|
|
Article: Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770, an Oral Compound to Treat CF; Emerging Data Shows Encouraging Response in CF Patients; Results Validate Investment in Venture Philanthropy Business Model.
- Article from:
- Ascribe Higher Education News Service
- Article date:
- March 27, 2008
CopyrightCOPYRIGHT 2008 AScribe. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Cystic Fibrosis Foundation
BETHESDA, Md., March 27 (AScribe Newswire) -- The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known ...